Skip to main content
. 2009 Oct;94(10):1456–1459. doi: 10.3324/haematol.2009.008276

Figure 2.

Figure 2.

(A) Therapeutic efficacy of EZN-2208 in an early- (first graph) versus advanced- (second graph) disease xenograft model of NHL (Daudi). CB17 SCID mice (6–10 mice per group) were inoculated i.v. with 1.5×107 Daudi cells per mouse. EZN-2208 or CPT-11 was given either as single (qd×1) or multiple (q2d×5) MTD doses. Early-disease model treatment started on day 1, and advanced-disease model treatment started on day 6. Control (▪), EZN-2208 at 30 mg/kg qd×1 (▴), CPT-11 at 60 mg/kg qd×1 (▵), EZN-2208 at 10 mg/kg q2d×5 (●), CPT-11 at 40 mg/kg q2d×5 (○). (B) Therapeutic efficacy of EZN-2208 in an early-versus advanced-disease xenograft models of NHL (DoHH2). CB17 SCID mice (6–10 mice per group) were inoculated i.v. with 1.0×107 DoHH2 cells per mouse. EZN-2208 or CPT-11 was given as multiple (q2d×5) MTD doses starting on day 2 or on day 11 post-administration of cells. Control (▪), EZN-2208 at 10 mg/kg q2d×5 starting on day 2 (▴), CPT-11 at 40 mg/kg q2d×5 starting on day 2 (▵), EZN-2208 at 10 mg/kg q2d×5 starting on day 11 (●), or CPT-11 at 40 mg/kg q2d×5 starting on day 11 (○).